# Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

> **NCT04409639** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Utah** · enrollment: 14 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia (CMML)

## Interventions

- **DRUG:** Cobimetinib

## Key facts

- **NCT ID:** NCT04409639
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-01-12
- **Primary completion:** 2025-04-02
- **Final completion:** 2026-08
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04409639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04409639, "Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT04409639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*